請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34429
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 呂紹俊 | |
dc.contributor.author | Ssu-Han Lin | en |
dc.contributor.author | 林偲涵 | zh_TW |
dc.date.accessioned | 2021-06-13T06:08:08Z | - |
dc.date.available | 2013-10-05 | |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-26 | |
dc.identifier.citation | 葛應欽等:台灣之口腔癌與嚼檳榔、吸菸、酒精消耗間的關聯性。口腔病理學及口腔內科學雜誌1995年第24卷。
李曜宏 (2008) NF-ĸB 及Oct-2在脂多醣透過MEK/ERK訊息傳遞路徑活化巨噬細胞表現G-CSF之過程中所扮演的角色。國立台灣大學醫學院生物化學暨分子生物學研究所碩士論文 Aoki, Y., Hirano, D., Kodama, H., Nishi, Y., and Nakamura, M. (1998). Stimulation of G-CSF gene expression in the macrophage cell line by contact with extracellular matrix proteins and a pre-B leukaemia cell line. Cytokine 10, 596-602. Asano, S., Urabe, A., Okabe, T., Sato, N., and Kondo, Y. (1977). Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood 49, 845-852. Benson, J.D., Chen, Y.N., Cornell-Kennon, S.A., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W.R., and Lengauer, C. (2006). Validating cancer drug targets. Nature 441, 451-456. Birgit Dibbert, M.W., Wilfried H. Nikolaizik, Peter Vogt, Martin H. Scho‥ni, Kurt Blaser, and Hans-Uwe Simon (1999). Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: A general mechanism to accumulate effector cells in inflammation. PNAS 96, 13330–13335. Boneberg, E.M., Hareng, L., Gantner, F., Wendel, A., and Hartung, T. (2000). Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 95, 270-276. Boneberg, E.M., and Hartung, T. (2002). Molecular aspects of anti-inflammatory action of G-CSF. Inflamm Res 51, 119-128. Borsch-Haubold, A.G., Pasquet, S., and Watson, S.P. (1998). Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 273, 28766-28772. Brandstetter, T., Ninci, E., Bettendorf, H., Perewusnyk, G., Stolte, J., Herchenbach, D., Sellin, D., Wagner, E., Kochli, O.R., and Bauknecht, T. (2001). Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation. Cancer 91, 1372-1383. Brown, C.Y., Lagnado, C.A., and Goodall, G.J. (1996). A cytokine mRNA-destabilizing element that is structurally and functionally distinct from A+U-rich elements. Proc Natl Acad Sci U S A 93, 13721-13725. Burgess, A.W., and Metcalf, D. (1980). Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. Int J Cancer 26, 647-654. Chakraborty, A., and Guha, S. (2007). Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 69, 1210-1215. Chakraborty, A., Hentzen, E.R., Seo, S.M., and Smith, C.W. (2003). Granulocyte colony-stimulating factor promotes adhesion of neutrophils. Am J Physiol Cell Physiol 284, C103-110. Chakraborty, A., White, S.M., and Guha, S. (2006). Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells. Urology 68, 208-213. Chou, Y.Y., Gao, J.I., Chang, S.F., Chang, P.Y., and Lu, S.C. (2011). Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2. FEBS J 278, 85-96. Chou, Y.Y., and Lu, S.C. (2011). Inhibition by rapamycin of the lipoteichoic acid-induced granulocyte-colony stimulating factor expression in mouse macrophages. Arch Biochem Biophys 508, 110-119. Chu, Y.W., Yang, P.C., Yang, S.C., Shyu, Y.C., Hendrix, M.J., Wu, R., and Wu, C.W. (1997). Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17, 353-360. Colotta, F., Re, F., Polentarutti, N., Sozzani, S., and Mantovani, A. (1992). Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80, 2012-2020. Cornish, A.L., Campbell, I.K., McKenzie, B.S., Chatfield, S., and Wicks, I.P. (2009). G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 5, 554-559. Dale, D.C., Bonilla, M.A., Davis, M.W., Nakanishi, A.M., Hammond, W.P., Kurtzberg, J., Wang, W., Jakubowski, A., Winton, E., Lalezari, P., et al. (1993). A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81, 2496-2502. de Wit, H., Dokter, W.H., Esselink, M.T., Halie, M.R., and Vellenga, E. (1993). Interferon-gamma enhances the LPS-induced G-CSF gene expression in human adherent monocytes, which is regulated at transcriptional and posttranscriptional levels. Exp Hematol 21, 785-790. Demetri, G.D., Zenzie, B.W., Rheinwald, J.G., and Griffin, J.D. (1989). Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 74, 940-946. Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3, 11-22. Duffy, M.J. (1992). The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10, 145-155. Dunn, S.M., Coles, L.S., Lang, R.K., Gerondakis, S., Vadas, M.A., and Shannon, M.F. (1994). Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood 83, 2469-2479. Erdem, N.F., Carlson, E.R., Gerard, D.A., and Ichiki, A.T. (2007). Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg 65, 1725-1733. Eyles, J.L., Roberts, A.W., Metcalf, D., and Wicks, I.P. (2006). Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol 2, 500-510. Falkenburg, J.H., Harrington, M.A., de Paus, R.A., Walsh, W.K., Daub, R., Landegent, J.E., and Broxmeyer, H.E. (1991). Differential transcriptional and posttranscriptional regulation of gene expression of the colony-stimulating factors by interleukin-1 and fetal bovine serum in murine fibroblasts. Blood 78, 658-665. Fujita, T., Ogasawara, Y., Naito, M., Doihara, H., and Shimizu, N. (2006). Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case. Surg Today 36, 63-67. Gabrilove, J.L., Welte, K., Lu, L., Castro-Malaspina, H., and Moore, M.A. (1985). Constitutive production of leukemia differentiation, colony-stimulating, erythroid burst-promoting, and pluripoietic factors by a human hepatoma cell line: characterization of the leukemia differentiation factor. Blood 66, 407-415. Gilbert, J.A., Goetz, M.P., Reynolds, C.A., Ingle, J.N., Giordano, K.F., Suman, V.J., Blair, H.E., Jenkins, R.B., Lingle, W.L., Reinholz, M.M., et al. (2008). Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther 7, 944-951. H.Nomura, I.I., M.Oheda, N.Kubota, M.Tamura,, and M.Ono, Y.U.a.S.A. (1986). Purification and characterization of human granulocyte colonystimulating factor (G-CSF). THE EMBO journal 5, 871-876. Hanazono, Y., Miyazono, K., Piao, Y.F., Taketazu, F., Chiba, S., Miyagawa, K., Hirai, H., Sakamoto, S., Miura, Y., and Yazaki, Y. (1992). Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases. Int J Hematol 55, 243-248. Hareng, L., Meergans, T., von Aulock, S., Volk, H.D., and Hartung, T. (2003). Cyclic AMP increases endogenous granulocyte colony-stimulating factor formation in monocytes and THP-1 macrophages despite attenuated TNF-alpha formation. Eur J Immunol 33, 2287-2296. Hill, C.P., Osslund, T.D., and Eisenberg, D. (1993). The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci U S A 90, 5167-5171. Hirasawa, K., Kitamura, T., Oka, T., and Matsushita, H. (2002). Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein. J Urol 167, 2130. Hock, B.D., Haring, L.F., Ebbett, A.M., Patton, W.N., and McKenzie, J.L. (2002). Differential effects of G-CSF mobilisation on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation. Bone Marrow Transplant 30, 733-740. JL Gabrilove, K.W., L Lu, H Castro-Malaspina and MA Moore (1985). Constitutive production of leukemia differentiation, colony-stimulating, erythroid burst-promoting, and pluripoietic factors by a human hepatoma cell line: characterization of the leukemia differentiation factor. Blood 66, 407-415. Johnson, G.L., and Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912. Joshita, S., Nakazawa, K., Sugiyama, Y., Kamijo, A., Matsubayashi, K., Miyabayashi, H., Furuta, K., Kitano, K., and Kawa, S. (2009). Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med 48, 687-691. K Welte, E.P., L Lu, J L Gabrilove, E Levi, R Mertelsmann, and M A Moore (1985). Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. PNAS 82, 1526-1530. Kamakura, S., Moriguchi, T., and Nishida, E. (1999). Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274, 26563-26571. Kamio, N., Akifusa, S., Yamaguchi, N., and Yamashita, Y. (2008). Induction of granulocyte colony-stimulating factor by globular adiponectin via the MEK-ERK pathway. Mol Cell Endocrinol 292, 20-25. Koeffler, H.P., Gasson, J., Ranyard, J., Souza, L., Shepard, M., and Munker, R. (1987). Recombinant human TNF alpha stimulates production of granulocyte colony-stimulating factor. Blood 70, 55-59. Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010). Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 107, 21248-21255. Lai, C.F., and Baumann, H. (1996). Interleukin-1 beta induces production of granulocyte colony-stimulating factor in human hepatoma cells. Blood 87, 4143-4148. Lyman, G.H., Kuderer, N.M., and Djulbegovic, B. (2002). Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112, 406-411. Matsumoto, Y., Mabuchi, S., Muraji, M., Morii, E., and Kimura, T. (2010). Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature. Int J Gynecol Cancer 20, 417-421. Mebratu, Y., and Tesfaigzi, Y. (2009). How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8, 1168-1175. Nagata, S., Tsuchiya, M., Asano, S., Kaziro, Y., Yamazaki, T., Yamamoto, O., Hirata, Y., Kubota, N., Oheda, M., Nomura, H., et al. (1986). Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319, 415-418. Nakajima, T., Kinoshita, S., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T., and Akira, S. (1993). Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A 90, 2207-2211. Nguyen, D.X., Bos, P.D., and Massague, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274-284. Ninci, E.B., Brandstetter, T., Meinhold-Heerlein, I., Bettendorf, H., Sellin, D., and Bauknecht, T. (2000). G-CSF receptor expression in ovarian cancer. Int J Gynecol Cancer 10, 19-26. Nishizawa, M., and Nagata, S. (1990). Regulatory elements responsible for inducible expression of the granulocyte colony-stimulating factor gene in macrophages. Mol Cell Biol 10, 2002-2011. Nishizawa, M., and Nagata, S. (1992). cDNA clones encoding leucine-zipper proteins which interact with G-CSF gene promoter element 1-binding protein. FEBS Lett 299, 36-38. Omura, N., Abe, S., Hirai, K., and Aoki, T. (1999). A case of granulocyte-colony stimulating factor producing gallbladder cancer. Am J Gastroenterol 94, 273-275. Park, S., Kim, E.S., Noh, D.Y., Hwang, K.T., and Moon, A. (2011). H-Ras-specific upregulation of granulocyte colony-stimulating factor promotes human breast cell invasion via matrix metalloproteinase-2. Cytokine 55, 126-133. Rheinwald, J.G., and Beckett, M.A. (1981). Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 41, 1657-1663. Roberts, A.W. (2005). G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 23, 33-41. Roberts, P.J., and Der, C.J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310. Rotondaro, L., Mazzanti, L., Mele, A., and Rovera, G. (1997). High-level expression of a cDNA for human granulocyte colony-stimulating factor in Chinese hamster ovary cells. Effect of 3'-noncoding sequences. Mol Biotechnol 7, 231-240. Sawazaki, H., Taki, Y., and Takeuchi, H. (2010). Granulocyte colony-stimulating factor (G-CSF) producing bladder cancer subsequently developed from recurrent non-muscle invasive bladder cancer. Int J Urol 17, 741-742. Sebolt-Leopold, J.S., and Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4, 937-947. Sergio Rutella, F.Z., Silvio Danese, Hassen Kared, and Giuseppe Leone (2005). Granulocyte colony-stimulating factor: a novel mediator of T Cell tolerance. J Immunol 175, 7085-7091. Shameem, I.A., Kurisu, H., Matsuyama, H., Shimabukuro, T., and Naito, K. (1994). Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cells. Cancer Immunol Immunother 38, 353-357. Shaw, G., and Kamen, R. (1986). A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667. Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y.G., and Ferrara, N. (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 106, 6742-6747. Stosser, S., Schweizerhof, M., and Kuner, R. (2011). Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med 89, 321-329. Sugimoto, C., Fujieda, S., Sunaga, H., Noda, I., Tanaka, N., Kimura, Y., Saito, H., and Matsukawa, S. (2001). Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells. Int J Cancer 93, 42-46. Vantaggiato, C., Formentini, I., Bondanza, A., Bonini, C., Naldini, L., and Brambilla, R. (2006). ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 5, 14. Watari, K., Asano, S., Shirafuji, N., Kodo, H., Ozawa, K., Takaku, F., and Kamachi, S. (1989). Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 73, 117-122. Welte, K., Platzer, E., Lu, L., Gabrilove, J.L., Levi, E., Mertelsmann, R., and Moore, M.A. (1985). Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 82, 1526-1530. Yamamoto, S., Takashima, S., Ogawa, H., Kuroda, T., Yamamoto, M., Takeda, A., and Nakmaura,H.(1999).Granulocyte-colony-stimulating-factor-producing hepatocellular carcinoma. J Gastroenterol 34, 640-644. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34429 | - |
dc.description.abstract | 顆粒性白血球群落刺激性因子 (granulocyte colony-stimulating factor, G-CSF)為醣蛋白的一種,可由單核球細胞、巨噬細胞、內皮細胞分泌,其主要功能為促進嗜中性白血球的分化與增生。G-CSF也可作用在其他細胞,例如穩定骨髓中單核球細胞、幹細胞的分化與增生,促進輔助性T細胞的活化與抑制發炎反應等,也因此目前G-CSF在治療疾病的臨床應用上相當廣泛。譬如在癌症治療方面,重組G-CSF目前被當作是化療佐劑的一種。由於接受化療的病人通常會有嗜中性白血球減少症,藉由G-CSF的作用來提高病人血液中的嗜中性白血球數量,以降低病人在接受治療過程中受到感染的風險。此外,在白血病病患接受化療之前,先給予重組G-CSF也被認為能提高癌細胞對治療藥劑的敏感性,藉此提高癌症治療的效率。然而當G-CSF表現過多時,也會造成免疫相關疾病。例如類風濕性關節炎常因為過多的G-CSF促使過量嗜中性白血球增生,最後導致嚴重的發炎反應產生。所以了解內生性G-CSF表現調控相當重要,但目前對此G-CSF在細胞中的調控尚未完全清楚。近年來有許多病例報告指出,在某些患有惡性腫瘤的病人檢體G-CSF有大量表現情形,隨著癌細胞侵略性增加,其G-CSF表現也相對提高。後續也有文獻提出,癌細胞表現的G-CSF會增加其轉移能力與侵略性。通常癌細胞的轉移與侵入對於癌症的致死率有高度相關性。因此了解G-CSF在癌細胞的表現與在癌細胞中是如何被調控對於癌症的治療具有一定的幫助。所以本研究的目的是想藉由不同侵入性的癌細胞來了解G-CSF的表現與G-CSF在癌細胞中的調控。
首先我們藉由RT-PCR與ELISA的實驗結果得知,在具較高轉移能力與侵入性的肺癌細胞CL1-5、乳癌細胞MDA-MB-231 IV1、口腔癌細胞SCC-15與HSC-3皆會表現較高量的G-CSF。接著以MEK1/2抑制劑PD98059和U0126處理細胞,發現在抑制磷酸化ERK1/2表現下,各癌細胞中的G-CSF表現量都明顯減少。此外,藉由shRNA knockdown MDA-MB-231 IV1細胞的ERK2蛋白表現,細胞中的G-CSF表現也明顯減少。我們也利用細胞激素TNF-α刺激MDA-MB-231 Parental細胞,發現MDA-MB-231 Parental細胞中G-CSF的表現量有明顯提高,且誘發的G-CSF表現會因U0126的處理而被抑制。在TNF-α的刺激之下,MDA-MB-231 Parental細胞中的磷酸化ERK1/2會提高表現,當U0126存在時,磷酸化ERK1/2的表現也隨即被抑制了。由此可知,癌細胞表現G-CSF會透過MAPK/ERK訊息傳遞路徑來調控。此外,我們藉由Western blot的方法也發現,在MDA-MB-231 IV1細胞中的磷酸化C/EBPβ表現量比Parental細胞表現的還要高,在MEK1/2抑制劑的處理之下,磷酸化的C/EBPβ表現量也被抑制了。由以上結果了解,MAPK/ERK訊息傳遞路徑去調控G-CSF表現會透過磷酸化的C/EBPβ。我們也用其他訊息傳遞路徑的蛋白激酶抑制劑去檢測癌細胞表現G-CSF是否會透過其他調控,由實驗結果顯示PI3K抑制劑,Ly294002會抑制SCC-15細胞的G-CSF表現。但對於其他細胞,PI3K、JNK和mTOR抑制劑都不影響G-CSF表現。由此可知在這些癌細胞中,對於G-CSF的調控主要是經由MAPK/ERK訊息傳遞路徑。最後我們檢測了G-CSF受器在細胞中的表現,發現這些癌細胞並不表現G-CSF受器。 由以上實驗結果,我們可以確定在具高度轉移與侵入性的癌細胞中會表現較高量的G-CSF。在這些癌細胞中,G-CSF的表現主要是透過MAPK/ERK與C/EBPβ訊息傳遞路徑的調控。但在癌細胞中,ERK是如何影響C/EBPβ對G-CSF的調控、G-CSF如何影響癌細胞轉移與侵入性的詳細機制仍須進一步的探討。 | zh_TW |
dc.description.abstract | Granulocyte colony-stimulating factor (G-CSF) is one of the glycoprotein that is secreted by monocytes, macrophages, fibroblasts and endothelia cells. The major function of G-CSF is to support the maturation, differentiation and proliferation of neutrophils. G-CSF mobilizes monocyte and stem cell from bone marrow into the blood and improves Type 2 T-helper cell response. G-CSF also induces the expression of anti-inflammatory cytokines in monocytes. In clinical, recombinant G-CSF (rG-CSF) has been used as an adjuvant for the prevention and amelioration of neutropenia following cancer chemotherapy. Case reports demonstrated that patients have received the injection of rG-CSF have a reduced risk of infection. Administrating rG-CSF before chemotherapy increases the sensitivity of cancer cells to drugs which then increases the efficacy of therapy. However, G-CSF over-expression is linked to inflammatory diseases, such as Rheumatoid Arthritis. G-CSF increases the number of neutrophils in bone marrow which leads to chronic inflammation-response in specific tissues. Understanding the regulation of G-CSF in immune and cancer cells is very important for disease therapy. In recent years, many case reports showed that G-CSF producing tumors are malignant and highly invasive; and the tumors grow rapidly and prognosis is poor. Therefore, G-CSF has been considered as a therapeutic condidate; and understanding how G-CSF is regulated in cancer cells is equally important. In this study, we investigated the expression levels of G-CSF in various cancer cells, and the involvement of ERK in the expression of G-CSF in these cancer cells.
We found that expression level of G-CSF is higher in cancer cells with higher migration and invasion ability, including CL1-5 lung cancer cell, MDA-MB-231 IV1 breast cancer cell, SCC-15 and HSC-3 oral cancer cells. When treating these cells with MEK1/2 inhibitor PD98059 and U0126, the cells resulted in inhibition of G-CSF expression in these cancer cells. Knockdown ERK2 in MDA-MB-231 IV1 breast cancer cell resulted in decreased G-CSF mRNA expression; while knockdown ERK1 resulted in higher G-CSF mRNA expression. Suggesting that activation of ERK2 is essential for G-CSF expression, but not ERK1. Treatment with TNF-α led to phosphorylation of ERK1/2 and up-regulation of G-CSF in MDA-MB-231 Parental cells. Pre-treatment with U0126 prevented ERK1/2 phosphorylation and G-CSF expression in these cells. According to these studies, we confirm that activation of ERK is essential for G-CSF expression in invasive cancer cells. Western blot showed that MDA-MB-231 IV1 cells express more phospho-C/EBPβ than MDA-MB-231 Parental cells. Treatment with U0126 inhibited C/EBPβ phosphorylation in MDA-MB-231 IV1 cells. It is possible that ERK regulates G-CSF, at least in part, via phospho-C/EBPβ. G-CSF expression in SCC-15 cells can be inhibited by LY294002, a PI3K inhibitor. However, other inhibitors, such as SP600125 and Rapamycin, have no effect on G-CSF expression in cancer cells used in this study. The results demonstrated that ERK2 is the major regulator of G-CSF expression in these cancer cells. Finally, we showed that the cancer cells we studied do not express G-CSF receptor. In summary, we demonstrate that G-CSF is up-regulated through an ERK2 dependent pathway in cancer cells with high level of migration and invasion. However, it is not clear how ERK regulates G-CSF, the mechanism underlie requires further studies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:08:08Z (GMT). No. of bitstreams: 1 ntu-100-R98442033-1.pdf: 1931590 bytes, checksum: 0b0a9fba4beef162d8db7fd67317e5e7 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要 iv
英文摘要 vi 名詞縮寫對照表 viii 第一章 緒論 1 第一節 文獻回顧 2 第二節 實驗動機與研究目的 10 第二章 材料與方法 12 第一節 實驗材料 13 第二節 細胞培養 14 第三節 以RT-PCR分析細胞內G-CSF mRNA表現 15 第四節 以real-time PCR分析細胞內基因mRNA表現 19 第五節 以西方墨點法 (Western Blot) 分析細胞內蛋白質表現 20 第六節 以Enzyme-Linked ImmunSorbent Assay (ELISA) 分析分泌性蛋白表現 22 第七節 以 RNA干擾抑制基因表現 23 第八節 統計分析與蛋白表現定量 25 第三章 結果 26 第四章 討論 33 第五章 圖表 40 附錄 61 參考文獻 64 | |
dc.language.iso | zh-TW | |
dc.title | ERK2調控G-CSF在侵略性癌細胞中的表現 | zh_TW |
dc.title | The role of ERK2 in G-CSF expression in invasive cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 許金玉,張淑芬,李明學,李家惠 | |
dc.subject.keyword | G-CSF,侵入性癌細胞,MAPK/ERK 訊息傳遞路徑,C/EBPβ,GCSF受器, | zh_TW |
dc.subject.keyword | G-CSF,G-CSF receptor,invasive cancer cell,MAPK/ERK pathway,C/EBPβ, | en |
dc.relation.page | 75 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-26 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。